AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph beginning at page 32, line 13 with the following rewritten paragraph:

Sagvolden, T. (2001) The spontaneously hypertensive rat as a model of ADHD. In: Stimulant drugs and ADHD: Basic and clinical neuroscience: pp. 221-237, M.V. Solanto, A.F.T. Arnstein, & F.X. Castellanos (Eds.), Oxford University Press. http://www.oup.co.uk/isbn/0-19-513371-4.

Please replace the paragraph beginning at page 6, line 14 with the following rewritten paragraph:

Among the many other administration regimens which are suitable for this invention are included those wherein the l-isomer is administered in a fashion such that: its plasma level is essentially constant throughout the day, e.g., in a smooth, sustained release fashion; or it achieves effective plasma levels before or after achievement of at least one effective plasma level of the d-isomer; or its plasma level is continuous or sustained throughout the day while the d-isomer is pulsed or otherwise administered in any of a wide variety of ways, including but not limited to immediate-release or the pulsing modes used in ADDERALL® ADDERALL XR®, or U.S. Pat. No. 6,322,819, WO 00/2305, U.S. Pat. No. 6,605,300, etc.; or it is administered simultaneously with the d-isomer several times throughout a day; or in various other regimens and variations, or combinations thereof. In all instances, the molar ratio of the two isomers at any given time can remain constant or can vary in either direction consistent with the foregoing, e.g., different ratios can be administered in different pulses, and the like. Either of the isomers can be used in free base form, or preferably the 1-isomer, and the other in salt form, or both can be salts or free base, or a mixture of salt and free base forms can be used, etc.